Beam Therapeutics Inc. — Director's Dealing 2020

Feb 11, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Beam Therapeutics Inc. (BEAM)
CIK: 0001745999
Period of Report: 2020-02-10

Reporting Person: Fishman Mark (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-10	Common Stock	C	17007	—	Acquired	17007	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-10	Series A-1 Preferred Stock	$	C	15768	Disposed		Common Stock (15768)	Direct
2020-02-10	Series A-2 Preferred Stock	$	C	1239	Disposed		Common Stock (1239)	Direct

Footnotes

F1: Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock and Series A-2 Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock or the Series A-2 Preferred Stock.